Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
To compare the impact on recurrence risk of adjuvant Sintilimab (a recombinant fully human anti-PD-1 monoclonal antibody) for patients with hepatocellular carcinoma and microvascular invasion (MVI) after hepatectomy.
Epistemonikos ID: 86c7090cf8d7373eacf472782e409189d3bdaa78
First added on: May 15, 2024